Foghorn Therapeutics (FHTX) director granted 28,000 stock options at $4.08 strike

Rhea-AI Filing Summary

Foghorn Therapeutics director Scott Biller received a stock option grant covering 28,000 shares of common stock at an exercise price of $4.08 per share. The option was granted as compensation and will vest in full on the first anniversary of the grant date, as long as he continues serving on the board of directors. Following this award, Biller holds 28,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Biller Scott

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	28,000	$4.08	$114K

Holdings After Transaction: Stock Options (Right to buy) — 28,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 28,000 options Exercise price: $4.08 per share Shares underlying options: 28,000 shares +2 more

5 metrics

Options granted 28,000 options Grant of stock options to director Scott Biller

Exercise price $4.08 per share Stock option strike price

Shares underlying options 28,000 shares Common stock underlying the options

Total options after grant 28,000 options Total derivative holdings following transaction

Option expiration June 23, 2036 Expiration date of the granted options

Key Terms

Stock Options (Right to buy), Grant, award, or other acquisition, underlying security, exercise price, +1 more

5 terms

Stock Options (Right to buy) financial

"security_title: "Stock Options (Right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

underlying security financial

"underlying_security_title: "Common Stock""

exercise price financial

"conversion_or_exercise_price: "4.0800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in full on the first anniversary financial

"The option vests in full on the first anniversary of the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 04:05 PM Accepted by SEC EDGAR 06/25/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Biller Scott

(Last) (First) (Middle)

99 COOLIDGE AVENUE

STE 500

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$4.08	06/24/2026		A		28,000		(1)	06/23/2036	Common Stock	28,000	$4.08	28,000	D

Explanation of Responses:

1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Remarks:

	/s/ Michael LaCascia, Attorney-in-Fact for Scott Biller	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Foghorn Therapeutics (FHTX) report for Scott Biller?

Foghorn Therapeutics reported that director Scott Biller received a grant of stock options for 28,000 shares of common stock at an exercise price of $4.08 per share as compensation, vesting after one year of continued board service.

How many FHTX stock options did Scott Biller acquire in this Form 4?

Scott Biller acquired stock options covering 28,000 shares of Foghorn Therapeutics common stock. These options were granted as a compensation award and are not an open-market purchase, but a derivative security that can be exercised at $4.08 per share in the future.

What is the exercise price and expiration date of Scott Biller’s FHTX options?

The granted stock options have an exercise price of $4.08 per share and an expiration date of June 23, 2036. This gives Biller the right to buy Foghorn Therapeutics common stock at $4.08 per share until that expiration date, subject to vesting.

When do Scott Biller’s Foghorn Therapeutics stock options vest?

The stock options granted to Scott Biller vest in full on the first anniversary of the grant date. Vesting is conditioned on his continued service on Foghorn Therapeutics’ board of directors through that one-year period, according to the footnote disclosure.

Is Scott Biller’s Form 4 transaction a market purchase of FHTX shares?

No, the Form 4 reflects a compensation-related grant of stock options, not a market purchase of common shares. The transaction is coded as an “A” award, giving Biller rights to acquire 28,000 shares at $4.08 per share if and when exercised.